Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
71 hedge funds and large institutions have $121M invested in Antares Pharma, Inc. in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 7 closing their positions.
120% more call options, than puts
Call options by funds: $121K | Put options by funds: $55K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
40% more capital invested
Capital invested by funds: $86.2M → $121M (+$34.4M)
6% more funds holding
Funds holding: 67 → 71 (+4)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$5.55M |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$985K |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$743K |
| 4 |
Morgan Stanley
New York
|
+$708K |
| 5 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$480K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$3.65M |
| 2 |
AC
Armistice Capital
New York
|
-$2.48M |
| 3 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
-$1.57M |
| 4 |
RA
Royce & Associates
New York
|
-$684K |
| 5 |
Millennium Management
New York
|
-$623K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Jane Street
New York
| – | -$19K | -11,254 | Closed |
|
77
JP Morgan Chase
New York
| – | -$15K | -8,992 | Closed |
|
78
Citigroup
New York
| – | -$10K | -6,162 | Closed |
|
ATRS Hedge Fund Activity: Q4 2016 in Review
71 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2016, worth a combined $121M — up 40% from $86.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATRS positions and 7 closed out — a net gain of 4 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.55M. The largest seller was Broadfin Capital, cutting an estimated $3.65M.
- 71 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2016, up from 67 in Q3 2016.
- Funds reported $121M of Antares Pharma, Inc. stock for Q4 2016, up 40% quarter-over-quarter.
- 11 funds opened new Antares Pharma, Inc. positions in Q4 2016 and 7 closed out, a net change of +4 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2016 was Perceptive Advisors, an estimated $5.55M added.
- The largest Antares Pharma, Inc. seller in Q4 2016 was Broadfin Capital, an estimated $3.65M sold.
Based on aggregated 13F filings for Q4 2016.